What this domain asks
Risk that authorization counts, approval rates, denial rates, appeal outcomes, response times, and automation claims use incompatible populations, definitions, periods, or denominators and therefore mislead buyers or the public.
The domain should retain its own evidence, decision owner, materiality criteria, exception path, and consequence even when it shares organization identity, workflow, or technology with adjacent domains. Aggregation can support oversight; it should not erase the evidence behind different risks or operating outcomes.
Buyer questions
- Is the metric reported at contract, issuer, plan, state, client, service-line, or enterprise level?
- Are drugs included or excluded, and are standard and expedited requests separated?
- Does response time begin when the provider sends the request or when the payer receives a complete request?
- Are approvals after appeal included in the overall approval and denial counts consistently?
- Can vendor automation claims be traced to a defined cohort, baseline, period, and independent reviewer?
- Can public reports be reproduced from case-level records without exposing protected information?
Mapped workflows
Authorization Status Tracking
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for authorization status tracking within this domain.
Metrics And Turnaround Reporting
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for metrics and turnaround reporting within this domain.
Audit Trail And Decision Provenance
A demonstration should show the trigger, source, accountable role, decision, exception, evidence, and downstream handoff for audit trail and decision provenance within this domain.
Authority context
CMS-0057-F
The rule requires impacted payers to improve prior authorization decision timeframes and denial reasons, publish aggregated prior authorization metrics, and implement FHIR-based Prior Authorization and other interoperability APIs. The prior authorization API provisions addressed by the final rule exclude drugs.
CMS-0062-P
The proposal would extend many electronic prior authorization, decision-time, transparency, API, and reporting policies to drugs and would adopt or update FHIR-based standards and implementation specifications for prior authorization transactions. The proposals are not final policy.
CMS Part C UM Annual Data Submission
The collection requires Medicare Advantage organizations to submit information about internal coverage criteria used by the organization or delegated entities to process Part C prior authorizations, increasing oversight of policy and delegation practices.
Relevant operating models
- Payer Utilization Management Workflow Platform
- Provider-Side Authorization And Patient-Access Automation
- Payer-Provider Authorization Network And Clearinghouse
- Utilization Review Decision Intelligence
- FHIR Interoperability And Compliance Infrastructure
Evidence boundary
Prior Auth Monitor does not provide patient-specific medical advice, determine coverage, authorize care, or establish final payment. Its records support organizational research and operating review. A provider's documented capability can identify a research candidate but cannot establish buyer-specific adequacy for this domain.